Chinook Therapeutics (KDNY) 10-Q 8 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Trading Symbol	KDNY
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Interactive Data Current	Yes
Entity Registrant Name	CHINOOK THERAPEUTICS, INC.
Entity Central Index Key	0001435049
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		62,896,299
Entity Current Reporting Status	Yes
Entity File Number	001-37345
Entity Tax Identification Number	94-3348934
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	400 Fairview Avenue North, Suite 900
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address Postal Zip Code	98109
City Area Code	(206)
Local Phone Number	485-7241

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 145,927	$ 181,724
Marketable securities	216,687	105,113
Accounts receivable	3,115	10,061
Prepaid expenses and other current assets	5,670	3,741
Total current assets	371,399	300,639
Marketable securities	42,587	68,215
Property and equipment, net	17,500	18,935
Restricted cash	2,074	2,074
Operating lease right-of-use assets	52,277	55,385
Investment in equity securities	41,200	41,200
Equity method investment	5,345	8,205
Intangible assets, net	25,151	26,009
In-process research & development	36,550	36,550
Goodwill	117	117
Other assets	7,042	6,474
Total assets	601,242	563,803
Current liabilities:
Accounts payable	4,907	8,580
Accrued and other current liabilities	17,373	17,104
Operating lease liabilities	4,701	4,401
Contingent value rights liability	2,500	10,000
Total current liabilities	29,481	40,085
Contingent value rights liability - non-current	22,509	24,591
Contingent consideration liability	4,220	5,160
Deferred tax liabilities	735	735
Operating lease liabilities, net of current maturities	37,166	39,589
Total liabilities	94,111	110,160
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized as of June 30, 2022 and December 31, 2021; no shares issued and outstanding at June 30, 2022 and December 31, 2021
Common stock, $0.0001 par value; 300,000 shares authorized as of June 30, 2022 and December 31, 2021; 62,873 and 54,761 shares issued and outstanding at June 30, 2022 and December 31, 2021	6	5
Additional paid-in capital	810,754	685,459
Accumulated deficit	(301,098)	(231,766)
Accumulated other comprehensive loss	(2,531)	(55)
Total stockholders’ equity	507,131	453,643
Total liabilities and stockholders’ equity	$ 601,242	$ 563,803

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock par value per share	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value per share	$ 0.0001	$ 0.0001
Common stock shares authorized	300,000,000	300,000,000
Common stock shares issued	62,873,000	54,761,000
Common stock shares outstanding	62,873,000	54,761,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]
Collaboration and license revenue	$ 418,000	$ 34,000	$ 3,115,000	$ 385,000
Operating expenses:
Research and development	30,023,000	22,787,000	56,275,000	48,484,000
General and administrative	8,635,000	7,768,000	16,503,000	17,311,000
Change in fair value of contingent consideration and contingent value rights liabilities	(1,984,000)	19,557,000	(3,022,000)	21,396,000
Amortization of intangible assets	429,000	422,000	858,000	842,000
Total operating expenses	37,103,000	50,534,000	70,614,000	88,033,000
Gain on sale of assets to equity method investment		7,227,000		7,227,000
Loss from operations	(36,685,000)	(43,273,000)	(67,499,000)	(80,421,000)
Other income (expense), net	767,000	(39,000)	672,000	(106,000)
Loss before income taxes and share of net loss of equity method investment	(35,918,000)	(43,312,000)	(66,827,000)	(80,527,000)
Income tax benefit	0	741,000	0	741,000
Share of net loss of equity method investment	(1,730,000)		(2,505,000)
Net loss	$ (37,648,000)	$ (42,571,000)	$ (69,332,000)	$ (79,786,000)
Net loss per share attributable to common stockholders, basic	$ (0.61)	$ (0.97)	$ (1.15)	$ (1.86)
Net loss per share attributable to common stockholders, diluted	$ (0.60)	$ (0.97)	$ (1.15)	$ (1.86)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	61,983	43,861	60,175	43,004
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	61,983	43,861	60,175	43,004
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax of $0	$ (501,000)	$ 99,000	$ (394,000)	$ 137,000
Unrealized gain (loss) on marketable debt securities, net of tax of $0	(493,000)	8,000	(2,082,000)	24,000
Total other comprehensive income (loss)	(994,000)	107,000	(2,476,000)	161,000
Comprehensive loss	$ (38,642,000)	$ (42,464,000)	$ (71,808,000)	$ (79,625,000)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]
Foreign currency translation adjustments, tax	$ 0	$ 0	$ 0	$ 0
Unrealized gain (loss) on marketable debt securities, tax	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 334,622	$ 4	$ 463,436	$ 11	$ (128,829)
Beginning balance, Shares at Dec. 31, 2020		42,282,000
Issuance of common stock upon exercise of stock options and warrants and vesting of restricted stock units	580		580
Issuance of common stock upon exercise of stock options and warrants and vesting of restricted stock units, shares		100,000
Stock-based compensation expense	2,478		2,478
Other comprehensive income (loss)	54			54
Net loss	(37,215)				(37,215)
Ending balance at Mar. 31, 2021	300,519	$ 4	466,494	65	(166,044)
Ending balance, Shares at Mar. 31, 2021		42,382,000
Beginning balance at Dec. 31, 2020	$ 334,622	$ 4	463,436	11	(128,829)
Beginning balance, Shares at Dec. 31, 2020		42,282,000
Issuance of common stock upon exercise of stock options, Shares	200,000
Net loss	$ (79,786)
Ending balance at Jun. 30, 2021	296,729	$ 4	505,168	172	(208,615)
Ending balance, Shares at Jun. 30, 2021		44,776,000
Beginning balance at Mar. 31, 2021	300,519	$ 4	$ 466,494	65	(166,044)
Beginning balance, Shares at Mar. 31, 2021		42,382,000
Issuance of common stock upon exercise of stock options and warrants,issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units	1,188	$ 178
Issuance of common stock upon exercise of stock options and warrants, issuance of common stock under employee stock purchase plan and vesting of restricted stock units, shares			1,188
Issuance of common stock under the at-the-market sales agreement,net of offering costs	33,891		$ 33,891
Issuance of common stock under the at-the-market sales agreement net of offering costs, shares		2,216,000
Stock-based compensation expense	3,595		3,595
Other comprehensive income (loss)	107			107
Net loss	(42,571)				(42,571)
Ending balance at Jun. 30, 2021	296,729	$ 4	505,168	172	(208,615)
Ending balance, Shares at Jun. 30, 2021		44,776,000
Beginning balance at Dec. 31, 2021	$ 453,643	$ 5	685,459	(55)	(231,766)
Beginning balance, Shares at Dec. 31, 2021	54,761,000	54,761,000
Issuance of common stock upon exercise of stock options and warrants and vesting of restricted stock units	$ 2,049	$ 1	2,048
Issuance of common stock upon exercise of stock options and warrants and vesting of restricted stock units, shares		356,000
Stock-based compensation expense	4,269		4,269
Other comprehensive income (loss)	(1,482)			(1,482)
Net loss	(31,684)				(31,684)
Ending balance at Mar. 31, 2022	426,795	$ 6	691,776	(1,537)	(263,450)
Ending balance, Shares at Mar. 31, 2022		55,117,000
Beginning balance at Dec. 31, 2021	$ 453,643	$ 5	685,459	(55)	(231,766)
Beginning balance, Shares at Dec. 31, 2021	54,761,000	54,761,000
Issuance of common stock upon exercise of stock options, Shares	356,000
Net loss	$ (69,332)
Ending balance at Jun. 30, 2022	$ 507,131	$ 6	810,754	(2,531)	(301,098)
Ending balance, Shares at Jun. 30, 2022	62,873,000	62,873,000
Beginning balance at Mar. 31, 2022	$ 426,795	$ 6	691,776	(1,537)	(263,450)
Beginning balance, Shares at Mar. 31, 2022		55,117,000
Issuance of common stock upon exercise of stock options and warrants,issuance of common stock under Employee Stock Purchase Plan, and vesting of restricted stock units	1,136		1,136
Issuance of common stock upon exercise of stock options and warrants, issuance of common stock under employee stock purchase plan and vesting of restricted stock units, shares		202,000
Issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs	113,082		113,082
Issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs, shares		7,554,000
Stock-based compensation expense	4,760		4,760
Other comprehensive income (loss)	(994)			(994)
Net loss	(37,648)				(37,648)
Ending balance at Jun. 30, 2022	$ 507,131	$ 6	$ 810,754	$ (2,531)	$ (301,098)
Ending balance, Shares at Jun. 30, 2022	62,873,000	62,873,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities
Net loss			$ (69,332)	$ (79,786)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense			1,702	1,552
Loss on disposal of property and equipment			234
Amortization of intangible assets	$ 429	$ 422	858	842
Non-cash operating lease expense			3,092	2,596
Stock-based compensation expense	4,760	3,595	9,029	6,073
Change in fair value of contingent consideration and contingent value rights liabilities	(1,984)	19,557	(3,022)	21,396
Accretion of discounts and amortization of premiums on marketable securities			706	(6)
Deferred income tax				(741)
Gain on sale of assets to equity method investment		(7,227)		(7,227)
Share of net loss of equity method investment	1,730		2,505
Changes in operating assets and liabilities:
Accounts receivable			6,946	(205)
Prepaid expenses and other assets			(2,503)	(153)
Accounts payable			(3,723)	5,610
Accrued and other liabilities			273	(3,956)
Operating lease liabilities			(2,105)	(1,413)
Deferred revenue				(95)
Net cash used in operating activities			(55,340)	(55,513)
Cash Flows from Investing Activities
Purchases of marketable securities			(152,213)	(105,328)
Proceeds from marketable securities			63,479	73,615
Purchases of property and equipment			(601)	(744)
Proceeds from sale of property and equipment				267
Net cash used in investing activities			(89,335)	(32,190)
Cash Flows from Financing Activities
Proceeds from issuance of common stock and accompanying pre-funded warrants in underwritten public offering, net of issuance costs			113,505
Proceeds from exercise of stock options and warrants and from Employee Stock Purchase Plan			3,185	1,768
Proceeds from at-the-market sales agreement, net of issuance costs				33,891
Previously incurred issuance costs related to an underwritten public offering paid during period			286
Payment of contingent value rights liability			(7,500)
Net cash provided by financing activities			108,904	35,659
Effect of exchange rate changes on cash, cash equivalents and restricted cash			(26)	84
Net decrease in cash, cash equivalents and restricted cash			(35,797)	(51,960)
Cash, cash equivalents and restricted cash at beginning of period			183,798	189,500
Cash, cash equivalents and restricted cash at end of period	148,001	137,540	148,001	137,540
Reconciliation of Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents	145,927	135,466	145,927	135,466
Restricted cash	2,074	2,074	2,074	2,074
Total cash, cash equivalents and restricted cash	$ 148,001	$ 137,540	148,001	137,540
Supplemental Cash Flow Information
Cash paid for amounts included in the measurement of lease liabilities			3,686
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Purchases of property and equipment included in accounts payable and in accrued and other current liabilities			87	$ 129
Issuance costs incurred but unpaid			$ 423

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Chinook Therapeutics, Inc. (the “Company”, “Chinook”, “we”, “our”, or “us”) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney diseases. On October 5, 2020, Aduro Biotech, Inc. (“Aduro”) completed its merger with Chinook Therapeutics U.S., Inc. (“Private Chinook”), pursuant to the terms of a merger agreement dated as of June 1, 2020, and amended on August 17, 2020, by which a wholly owned subsidiary Our lead clinical program is atrasentan, a potent and selective endothelin receptor antagonist. In March 2021, we initiated the phase 3 ALIGN trial of atrasentan for IgA nephropathy (“IgAN”) and in April 2021, we initiated the phase 2 AFFINITY basket trial of atrasentan for proteinuric glomerular diseases. Our second product candidate, BION-1301, is an anti-APRIL monoclonal antibody in phase 1/2 development for patients with IgAN. Our third product candidate is CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary and idiopathic hyperoxaluria. In April 2022, we initiated a phase 1 clinical trial of CHK-336 in healthy volunteers. In addition, we are building our precision medicine pipeline through research and discovery programs for other rare, severe chronic kidney diseases. We were incorporated in Delaware and are headquartered in Seattle, Washington.

Basis of Presentation and Conso

Basis of Presentation and Consolidation, Use of Estimates and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Consolidation, Use of Estimates and Recent Accounting Pronouncements	2. Basis of Presentation and Consolidation, Use of Estimates and Recent Accounting Pronouncements Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of financial information. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or for any other future year. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2021 included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 17, 2022. The condensed consolidated financial statements include the accounts of Chinook Therapeutics, Inc. and our wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of expenses during the reporting periods. Such estimates include the valuation of intangible assets, acquired property and equipment, investments, contingent value rights (“CVR”) liability, contingent consideration liability, lease right-of-use assets, and lease obligations, as well as Risks and Uncertainties We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of our products and processes and clinical efficacy and safety of our products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. Our product candidates are still in development and, to date, none of our product candidates have been approved for sale and, therefore, we have not generated any revenue from product sales. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate revenue from product sales. We operate in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees, consultants and other third parties. Moreover, the current COVID-19 pandemic, which is impacting worldwide economic activity, poses risk that we or our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the start-up and conduct of our clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may Recent Accounting Pronouncements Recent Accounting Pronouncements, Not Yet Adopted In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recently Adopted Accounting Pronouncements In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40)

Reverse Merger and Contingent V

Reverse Merger and Contingent Value Rights	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Reverse Merger and Contingent Value Rights	3. Reverse Merger and Contingent Value Rights We completed our Merger with Aduro on October 5, 2020. At the effective time of the Merger, we also entered into an agreement pursuant to which Aduro’s common stockholders of record as of the close of business on October 2, 2020 received one CVR for each outstanding share of Aduro common stock held by such stockholder on such date (the “CVR Agreement”). Each CVR represents the contractual right to receive payments from us upon the receipt of consideration resulting from milestones and royalties from certain pre-existing agreements and the disposition or licensing of certain of Aduro’s non-renal assets, net of deductions permitted under the CVR Agreement, including taxes and certain other expenses.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities	6 Months Ended
	Jun. 30, 2022
Cash And Cash Equivalents [Abstract]
Cash, Cash Equivalents and Marketable Securities	4. Cash, Cash Equivalents and Marketable Securities Cash, cash equivalents and marketable securities consisted of the following (in thousands): June 30, 2022 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Cash $ 25,004 $ — $ — $ 25,004 Money market funds 53,850 — — 53,850 Commercial paper 62,094 — (10 ) 62,084 U.S. government and agency securities 4,990 — (1 ) 4,989 Total cash and cash equivalents $ 145,938 $ — $ (11 ) $ 145,927 Marketable securities: Commercial paper $ 49,972 $ 1 $ (51 ) $ 49,922 U.S. government and agency securities 143,944 2 (1,275 ) 142,671 Corporate debt securities 67,560 1 (880 ) 66,681 Total marketable securities $ 261,476 $ 4 $ (2,206 ) $ 259,274 December 31, 2021 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Cash $ 44,499 $ — $ — $ 44,499 Money market funds 117,023 — — 117,023 Commercial paper 16,898 — (1 ) 16,897 Corporate debt securities 3,306 — (1 ) 3,305 Total cash and cash equivalents $ 181,726 $ — $ (2 ) $ 181,724 Marketable securities: Commercial paper $ 34,978 $ — $ (10 ) $ 34,968 U.S. government and agency securities 85,309 1 (88 ) 85,222 Corporate debt securities 53,172 4 (38 ) 53,138 Total marketable securities $ 173,459 $ 5 $ (136 ) $ 173,328 The amortized cost and estimated fair value of our available-for-sale marketable securities by contractual maturity are summarized below as of June 30 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Mature in one year or less $ 217,966 $ 2 $ (1,281 ) $ 216,687 Mature after one year through two years 43,510 2 (925 ) 42,587 Total available-for-sale marketable securities $ 261,476 $ 4 $ (2,206 ) $ 259,274 For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be non-credit related. As of June 30

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements We record certain financial assets and liabilities at fair value in accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 820 on fair value measurements. As defined in the guidance, fair value, defined as an exit price, represents the amount that would be received to sell an asset or pay to transfer a liability in an orderly transaction between market participants. As a result, fair value is a market-based approach that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering these assumptions, the guidance defines a three-tier valuation hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1: Unadjusted quoted prices in active, accessible markets for identical assets or liabilities. Level 2: Quoted prices in markets that are not active or financial instruments for which all significant Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The determination of a financial instrument’s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. We consider observable data to be market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): June 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 78,854 $ — $ — $ 78,854 Commercial paper — 62,084 — 62,084 U.S. government and agency securities — 4,989 — 4,989 Total cash and cash equivalents 78,854 67,073 — 145,927 Marketable securities: Commercial paper — 49,922 — 49,922 U.S. government and agency securities — 142,671 — 142,671 Corporate debt securities — 66,681 — 66,681 Total marketable securities — 259,274 — 259,274 Total fair value of assets $ 78,854 $ 326,347 $ — $ 405,201 Liabilities: Contingent value rights liability $ — $ — $ 25,009 $ 25,009 Contingent consideration liability — — 4,220 4,220 Total fair value of liabilities $ — $ — $ 29,229 $ 29,229 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 161,522 $ — $ — $ 161,522 Commercial paper — 16,897 — 16,897 Corporate debt securities — 3,305 — 3,305 Total cash and cash equivalents 161,522 20,202 — 181,724 Marketable securities: Commercial paper — 34,968 — 34,968 U.S. government and agency securities — 85,222 — 85,222 Corporate debt securities — 53,138 — 53,138 Total marketable securities — 173,328 — 173,328 Total fair value of assets $ 161,522 $ 193,530 $ — $ 355,052 Liabilities: Contingent value rights liability $ — $ — $ 34,591 $ 34,591 Contingent consideration liability — — 5,160 5,160 Total fair value of liabilities $ — $ — $ 39,751 $ 39,751 Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Other cash equivalents and marketable securities, such as commercial paper, U.S. government and agency securities, and corporate debt securities are classified within Level 2 of the fair value hierarchy as the valuation is obtained from third-party pricing services, which utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, estimated interest rates based on the issuer credit rating and term, and other observable inputs. The following table presents a summary of the changes in the fair value of our Level 3 financial instruments (in thousands): Contingent Value Rights Liability Contingent Consideration Liability Balance at December 31, 2021 $ 34,591 $ 5,160 Net change in fair value upon remeasurement (2,082 ) (940 ) Payment of contingent value rights liability (7,500 ) — Balance at June 30, 2022 $ 25,009 $ 4,220 The fair values of the CVR and contingent consideration liabilities are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the CVR and the contingent consideration liabilities, we used the income approach, primarily discounted cash flow models. The discounted cash flow models require the use of significant judgment, estimates and assumptions, including estimated revenues and costs, the probability of technical and regulatory success, and discount rates. The fair value of the CVR and the contingent consideration liabilities decreased during the six months ended June 30, 2022 by $10.5 million, which included $7.5 million paid to CVR holders in the second quarter of 2022, resulting from a development milestone recognized in the fourth quarter of 2021 under the license agreement with Merck for MK-5890, as well as a change in fair value resulting from remeasurement of the liabilities. For the three and six months ended June 30, 2022, the change in fair value of the CVR and the contingent consideration liabilities from remeasurement was a decrease of $2.0 million and $3.0 million, respectively, and was recorded in the condensed consolidated statement of operations and comprehensive loss. The decrease was primarily due to higher discount rates in 2022 driven by changes in market interest rates, which lowered the present value of future cash flows and a decrease in the estimated value of our preferred shares in Sairopa B.V. (“Sairopa”). We will hold the shares in Sairopa until there is a liquidation event, at which time, in accordance with the CVR agreement, 50% of any net proceeds will accrue to the benefit of the CVR holders, net of deductions permitted under the CVR Agreement, including taxes and certain other expenses. Refer to Note 10 “Equity Method Investment” for more information. For the three and six months ended June 30, 2021, the fair value of the CVR and the contingent consideration liabilities increased by $19.6 million and $21.4 million, respectively, and was recorded in the condensed consolidated statement of operations and comprehensive loss. The increase was primarily due to a change in the estimate of the potential future proceeds derived from the license agreement with Merck, which included the impact of Merck informing us in the second quarter of 2021 that they intended to evaluate the product candidate MK-5890 in a phase 2 clinical study for a new indication, and a change in the fair value from the sale of certain of our non-renal assets in exchange for preferred shares in Sairopa during the second quarter of 2021.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2022
Property Plant And Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2022 2021 Research and lab equipment $ 3,405 $ 3,366 Computer equipment and software 1,349 1,497 Furniture and fixtures 1,346 1,224 Leasehold improvements 17,010 16,976 Total property and equipment 23,110 23,063 Total accumulated depreciation (5,610 ) (4,128 ) Property and equipment, net $ 17,500 $ 18,935 Depreciation and amortization expense for property and equipment for both the three months ended June 30, 2022 and 2021 was $0.8 million, and was $1.7 million and $1.5 million for the six months ended June 30, 2022 and 2021, respectively. Approximately $2.6 million of our property and equipment, net as of June

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets Goodwill The gross carrying amount and net book value of goodwill was $0.1 million at June 30, 2022, all of which resulted from the Merger. We test Intangible assets The gross carrying amounts and net book value of intangible assets were as follows (in thousands): June 30, 2022 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 2,752 $ 23,933 In-place lease 1,433 215 1,218 Total intangible assets with finite lives 28,118 2,967 25,151 Acquired in-process research & development ("IPR&D") assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 2,967 $ 61,701 December 31, 2021 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 1,968 $ 24,717 In-place lease 1,433 141 1,292 Total intangible assets with finite lives 28,118 2,109 26,009 Acquired IPR&D assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 2,109 $ 62,559 Intangible assets are carried at cost less accumulated amortization and impairment. Amortization is over periods of 9 to 17 years, with an original weighted average period of 16.7 years, and the amortization expense is recorded in operating expenses. We test our acquired IPR&D assets for impairment on an annual basis, or more frequently if an impairment indicator exists. Amortization expense was $0.4 million for both the three months ended June 30 June 30, 2022 and 2021, respectively June 30 Year Ending December 31, Estimated Amortization Expense 2022 (remaining six months) $ 864 2023 1,733 2024 1,733 2025 1,733 2026 1,733 Thereafter 17,355

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities And Other Liabilities [Abstract]
Accrued and Other Current Liabilities	8. Accrued and other current liabilities consisted of the following (in thousands): June 30, December 31, 2022 2021 Research and development costs $ 11,157 $ 8,397 Compensation and benefits 4,844 6,455 Sublease rent and security deposit 299 1,067 Business taxes and licensing fees 331 421 Consulting and outside services 711 424 Other 31 340 Total accrued and other current liabilities $ 17,373 $ 17,104

Investment in Equity Securities

Investment in Equity Securities	6 Months Ended
	Jun. 30, 2022
Investments Debt And Equity Securities [Abstract]
Investment in Equity Securities	9. Investment in Equity Securities In November 2021, we entered into agreements related to the formation of SanReno, a corporation established to develop, manufacture and commercialize kidney disease therapies in mainland China, Hong Kong, Macau, Taiwan and Singapore (collectively, the “Territory”). In connection with the formation of SanReno and pursuant to a license agreement entered into between Chinook and SanReno in November 2021 (the “China License Agreement”), Chinook granted SanReno exclusive licenses under certain intellectual property to develop and commercialize atrasentan and BION-1301 in the Territory for use in all human indications. In return, Chinook received 40.0 million Series A preferred shares in SanReno representing 50% ownership of the outstanding voting securities and a warrant to purchase a total of 5.0 million common shares of SanReno at an exercise price of $0.01 per share upon the attainment of regulatory exclusivity for atrasentan in the Territory. Such warrant will only be exercisable if and provided that SanReno obtains, before the 10-year anniversary of the closing of the formation of SanReno, the regulatory exclusivity for atrasentan in China for at least three years commencing from the New Drug Application approval by the National Medical Product Administration of China. The warrant will have a five-year In connection with the formation of SanReno in November 2021, Chinook also entered into a Shareholders Agreement (the “Shareholders Agreement”) providing for certain rights and obligations of SanReno and its shareholders. Pursuant to the Shareholders Agreement, Chinook has the right to designate an individual for election to the board of directors of SanReno and SanReno has agreed that certain specified events (including certain liquidation events) shall require the approval of shareholders of SanReno holding a supermajority of SanReno’s Series A preferred shares. The Shareholders Agreement terminates by mutual consent of the parties, and automatically terminates upon the dissolution of SanReno or immediately prior to the consummation of a qualified initial public offering. We account for the investment in SanReno in accordance with the provisions of ASC Topic 321, Investments – Equity Securities Pursuant to the terms of the Series A preferred stock, we are entitled to non-cumulative dividends at 8% of our initial investment, payable when and if declared by the board of directors of SanReno. Dividends from our investment in equity securities, if declared, are reflected in the consolidated statements of operations and comprehensive loss. There were no dividends declared during the three and six months ended June 30, 2022.

Equity Method Investment

Equity Method Investment	6 Months Ended
	Jun. 30, 2022
Equity Method Investments And Joint Ventures [Abstract]
Equity Method Investment	10. Equity Method Investment In April 2021, we entered into a definitive agreement with Sairopa B.V., a private company created by Van Herk Royalty B.V. and D.S. Chahal (the “Sairopa Investors”) to acquire certain non-renal assets of Chinook in exchange for preferred stock in Sairopa. We will hold such shares until such time as there is a liquidation event, as defined in the shareholders agreement, in Sairopa. In accordance with the CVR Agreement, 50% of any net proceeds received from this transaction by way of a liquidation event of Sairopa by October 4, 2030, net of deductions permitted under the CVR Agreement, including taxes and certain other expenses, will accrue to the benefit of the CVR holders. As of June 30, 2022, we own a 44% interest in Sairopa. We determined that we have the ability to exercise significant influence over Sairopa but do not have a controlling interest. Therefore, the investment in Sairopa was accounted for using the equity method. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, and participation in policy-making decisions. The Sairopa Investors provided an initial capitalization of 12.5 million Euros. We recorded the equity method investment at $10.0 million, which is the fair value of the equity received by us in exchange for the non-renal assets. Our equity method investment was recorded at cost at inception and is adjusted each period for our share of the investee’s income or loss, which is reported in our consolidated statements of operations and comprehensive loss on a one quarter lag. We assess our equity method investment for impairment whenever events or changes in circumstances indicate that the carrying value of the investment may not be recoverable.

Collaboration and License Agree

Collaboration and License Agreements	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration and License Agreements	11. Collaboration and License Agreements SanReno Therapeutics In November 2021, we entered into the China License Agreement, pursuant to which we granted SanReno exclusive licenses under certain intellectual property to develop, manufacture and commercialize for atrasentan and BION-1301 in the Territory. Refer to Note 9 “Investment in Equity Securities” for further details on the agreements executed with SanReno. We evaluated the China License Agreement under ASC Topic 606 and determined that the China License Agreement represents a contract with a customer. We identified the following performance obligations: (i) the licenses to develop, manufacture and commercialize atrasentan and BION-1301; (ii) our obligation to transfer know-how for the licensed product candidates (“Technology Transfers”); (iii) manufacturing and supply services; and (iv) opt-in global studies. We determined that the preferred shares we received in SanReno of $40.0 million plus the warrant granted to us of $1.2 million constituted the entire consideration to be included in the total transaction price at the outset of the arrangement. Further, in determination of the performance obligations under the license agreements, the stand-alone selling prices of the performance obligations and our responsibility in the development activities have also been considered. Accordingly, the licenses, Technology Transfers, manufacturing and supply services, and opt-in global studies are all considered distinct performance obligations. Since both licensed product candidates are in the later stages of development, we determined that both licenses have significant stand-alone functionalities as of contract inception. SanReno can begin deriving benefit from the licenses prior to the Technology Transfers being completed. The Technology Transfers will be completed upon request of SanReno and are separate from the transfer of the licenses, which occurred at contract inception. The estimated standalone selling price for the Technology Transfers was determined by estimating the costs of satisfying the performance obligation, plus an appropriate margin for such services. Pursuant to the China License Agreement, SanReno will reimburse the manufacturing and supply services at cost plus a mark-up and will reimburse the opt-in global studies at cost, which represent pass-through fees from third-party vendors, including clinical research organization. Revenue attributable to the manufacturing and supply services and opt-in global studies will be recognized as incurred. For the three months ended June 30, 2022, we recognized revenue of $0.4 million under the China License Agreement for costs reimbursed related to manufacturing and supply services. For the six months ended June 30, 2022, we recognized revenue of $3.1 million under the China License Agreement for costs reimbursed related to opt-in global studies and manufacturing and supply services. We are also eligible to receive a progress-dependent milestone payment of up to approximately $25.0 million with respect to BION-1301. Under the China License Agreement, SanReno is also obligated to pay Chinook royalty payments at a percentage in the low teens based on net sales of atrasentan in the Territory on the portion of annual net sales in excess of a pre-determined amount, which royalty will be payable until the expiration of all licensed patents covering the sale of atrasentan in the Territory. The China License Agreement expires on a licensed product-by-licensed product basis on the latest of: (i) the expiration of the royalty term for atrasentan, (ii) the expiration of the last valid claim of a licensed patent for BION-1301 in the Territory. The parties may terminate the China License Agreement pursuant to terms specified in the agreement. Chinook and SanReno also have reciprocal rights of first negotiation in their respective territories for certain future kidney disease products developed or in-licensed by either company. Chinook retains full rights to atrasentan and BION-1301 outside of the Territory. The potential progress-dependent cash milestone payment that we are eligible to receive was excluded from the total transaction price, as the milestone amount is fully constrained based on the probability of achievement. Accordingly, any future milestone payment received under the agreement will be recorded upon or over a period following receipt. Further, we will apply the exception under ASC Topic 606 for variable consideration related to sales-or-usage based royalties received in exchange for licensed intellectual property associated with atrasentan, therefore the royalties are not included in the transaction price until the licensee sells product. No progress-dependent milestone payments and royalties were earned during the three and six months ended June 30, 2022. AbbVie Ireland Unlimited Company In December 2019, we entered into a license agreement (the “License Agreement”) with AbbVie Ireland Unlimited Company (“AbbVie”), which granted us an exclusive license to develop and commercialize atrasentan, an endothelin receptor antagonist. Under the agreement, we assumed all global development and commercialization responsibilities for atrasentan. In consideration of the license and rights granted under the License Agreement, we made an upfront cash payment and issued 2.0 million shares of common stock for total consideration of $6.7 million to AbbVie. We concluded that this transaction should be accounted for as an asset purchase, and as such, recorded the associated expense within research and development expense in the statements of operations and comprehensive loss, as the product has not reached technological feasibility and does not have alternative future use. Under the License Agreement, we are obligated to make contingent development, regulatory and commercial milestone payments of up to a maximum of $135 million in the aggregate, as well as pay royalties on the worldwide net sales of licensed products ranging from upper-single-digit to high-teen percentages. We did not recognize any milestone payments for the three and six months ended June 30 June 30 Merck In connection with the Merger, we became party to an agreement with Merck. The agreement sets forth the parties’ respective obligations for development, commercialization, regulatory and manufacturing and supply activities for antibody product candidates. All performance obligations of Aduro were completed prior to the Merger. We are eligible to receive future contingent payments, including up to $287.0 million in potential development milestone payments, and up to $135.0 million in commercial and net sales milestones for a product candidate. In addition, we are eligible to receive royalties at percentages in the mid-single digits to low teens based on net sales of the product. Future milestone payments and royalties will be recognized as revenue when earned as we have no performance obligations under this agreement. Any such milestones and royalties earned prior to October 4, 2030 will be payable by us to the CVR holders, net of deductions permitted under the CVR Agreement, including taxes and certain other expenses. A $10.0 million development milestone was earned in the fourth quarter of 2021 and received in 2022. We paid this milestone, net of taxes and expenses, to the CVR holders in the second quarter of 2022. Eli Lilly and Company In connection with the Merger, we assumed an ongoing research collaboration and exclusive license agreement with Eli Lilly and Company (“Lilly”) for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases. Our only remaining performance obligation under the agreement was to perform research services through 2021, for which we were reimbursed up to a specified amount. We are eligible to receive future contingent milestone payments of up to approximately $464.9 million per licensed product and tiered royalties on net sales at percentages in the single digits. We determined that the potential milestone payments are not considered probable of being achieved and, accordingly, such milestones will be recognized as revenue when earned. For the three and six months ended June 30, 2021, we recognized revenue of less than $0.1 million and $0.4 million, respectively, under the Lilly agreement.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Leases We have a total of four operating leases as of June 30 In June 2021, we entered into a sublease agreement for office space in Seattle, Washington (“Seattle Sublease”), which we use as our corporate headquarters. The Seattle Sublease commenced on July 1, 2021 and continues for a period of 58 months. The aggregate estimated base rent payments due over the remaining term of the Seattle Sublease is approximately $4.8 million. As of June 30 June 30 June We maintain a letter of credit as security for a facility lease that expires in 2029. The letter of credit is collateralized by a certificate of deposit in the amount of $1.8 million, which is classified as long-term restricted cash in our condensed consolidated balance sheet as of June 30, 2022. Additionally, we maintain a letter of credit as a security deposit for a facility lease that expires in 2026. The letter of credit is collateralized by a certificate of deposit in the amount of $0.3 million, which is classified as long-term restricted cash in our condensed consolidated balance sheet as of June 30, 2022. The maturity of our operating lease liabilities as of June 30, 2022 is as follows (in thousands): Undiscounted Lease Payments Amounts 2022 (remaining six months) $ 3,800 2023 7,695 2024 7,850 2025 8,009 2026 7,158 Thereafter 18,919 Total undiscounted lease payments 53,431 Present value adjustment (11,564 ) Total net lease liability $ 41,867 Net lease liability – current $ 4,701 Net lease liability - non-current 37,166 Total net lease liability $ 41,867 Rent expense recognized for operating leases was $2.3 million and $2.1 million for the three months ended June 30 June 30, 2022 and 2021, respectively June 30 June The following summarizes additional information related to our operating leases: June 30, 2022 December 31, 2021 Weighted-average remaining lease terms (in years) Operating leases 6.9 7.4 Weighted-average discount rate Operating leases 7.5% 7.5% Indemnification Agreements In the ordinary course of business, we enter into agreements that may include indemnification provisions. Pursuant to such agreements, we may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments we could be required to make under these provisions is not determinable. We have never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. We have also entered into indemnification agreements with our directors and officers that require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. We currently maintain directors’ and officers’ liability insurance. Legal Proceedings From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Management believes that there are no actions pending against us currently, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows. Other Commitments We have various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of our business. All contracts are terminable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, we would only be obligated for the products or services that we had received at the time the termination became effective as well as non-cancelable and non-refundable obligations, including payment obligations for costs or expenses incurred by the vendor for products or services before the termination became effective. In the case of terminating a clinical trial agreement at a particular site, we would also be obligated to provide continued support for appropriate medical procedures at that site until completion or termination.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Common Stock	13. Common Stock Issuance of Securities through an Underwritten Public Offering In May 2022, we completed an underwritten public offering of 7.6 million shares of our common stock at a price to the public of $14.00 per share, which included the exercise in full of the underwriters’ option to purchase an additional 1.1 million shares of our common stock in June 2022. In addition, we sold to certain investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1.1 million shares of common stock at a purchase price of $13.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such warrant. The Pre-Funded Warrants are exercisable at any time after the date of issuance and do not expire. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage, but not in excess of 19.99%, by providing at least 61 days’ prior notice to Chinook. The underwritten public offering resulted in gross proceeds to us of $120.7 million, before $7.7 million of underwriting discounts and commissions and estimated offering expenses. We evaluated the Pre-Funded Warrants for liability or equity classification in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity , and determined that equity treatment was appropriate because the Pre-Funded Warrants did not meet the definition of liability instruments. The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the share of common stock with which they were issued, are immediately exercisable, do not include repurchase rights, cash settlement, or other put provisions, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return. We valued the Pre-Funded Warrants to purchase 1.1 million shares of common stock at an aggregate value of $15.0 million. The value of $13.9999 per pre-funded warrant was measured on the grant date based on the common stock price in the underwritten public offering of $14.00 per share, less the $0.0001 per share exercise price of the warrant. As of June 30, 2022, none of the Pre-Funded Warrants have been exercised. Additionally, as of June 30, 2022, none of the 3.6 million pre-funded warrants to purchase common stock, issued in connection with the November 2021 public offering, have been exercised. Refer to Note 13 “Common Stock” in our Annual Report on Form 10-K for more information. At-the-Market Sales Agreement In April 2021, we entered into an “at-the-market” sales agreement (the “2021 Sales Agreement”), with Cantor Fitzgerald & Co. and SVB Leerink LLC, through which we may offer and sell shares of our common stock having an aggregate offering of up to $75.0 million through our sales agents, Cantor Fitzgerald & Co. and SVB Leerink LLC. We will pay the sales agents a commission of up to 3% of the gross proceeds of sales made through the 2021 Sales Agreement. In April 2021, we sold 2.2 million shares for $33.9 million in net proceeds under the 2021 Sales Agreement. As of June 30, 2022, w e have $ 40.0 million remaining under the 2021 Sales Agreement, which is subject to the continued effectiveness of our shelf registration statement on Form S-3 (Registration No. 333-255099) that expires on April 7, 2024 , or upon an effective replacement shelf registration statement. Restricted Stock Awards (“RSAs”) The following table summarizes RSA activity: RSAs Outstanding Number of RSAs (in thousands) Weighted- Average Grant Date Fair Value Per Share Balance—December 31, 2021 99 $ 0.00034 Vested (47 ) 0.00034 Cancelled or forfeited (6 ) 0.00034 Balance—June 30, 2022 46 $ 0.00034 The fair value of RSAs vested during the six months ended June

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	14. Stock-Based Compensation Equity Incentive Plans In February 2019, Private Chinook adopted the 2019 Equity Incentive Plan (the “2019 Plan”). In connection with the Merger, we assumed Aduro’s two equity incentive plans, the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2009 Stock Incentive Plan (the “2009 Plan,” and collectively the “Aduro Plans” and together with the 2019 Plan, the “Plans”). No additional grants may be made from the 2009 Plan; however, shares subject to awards granted under the 2009 Plan remain subject to the terms of the 2009 Plan. As of June 30, 2022 and December 31, 2021, there were 1.7 million and 1.4 million shares available for future grant, respectively. In connection with the Merger, we assumed Aduro’s 2015 employee stock purchase plan (“2015 ESPP”). As of June 30, 2022 and December 31, 2021, there were 1.2 million and 0.7 million shares available for future issuance under the 2015 ESPP, respectively. Stock option activity under the Plans is set forth below: Number of Shares Underlying Options (in thousands) Weighted- Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Balance—December 31, 2021 5,842 $ 12.73 $ 7.00 $ 34,928 Granted 2,026 13.49 Exercised (356 ) 7.26 Canceled or forfeited (525 ) 12.99 Balance—June 30, 2022 6,987 $ 13.21 $ 7.52 $ 42,093 Options exercisable—June 30, 2022 2,802 $ 14.47 $ 5.41 $ 20,580 Options vested and expected to vest—June 30, 2022 6,987 $ 13.21 $ 7.52 $ 42,093 The aggregate intrinsic values of options outstanding, exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the market price for shares of our common stock as of June 30, 2022. Options for 0.4 million and 0.2 million shares of our common stock were exercised during the six months ended June 30, 2022 and 2021, respectively, with an intrinsic value of $2.7 million and $2.5 million, respectively. Restricted stock unit (“RSU”) activity under the Plans is set forth below: RSUs Outstanding Number of RSUs (in thousands) Weighted- Average Grant Date Fair Share Balance—December 31, 2021 823 $ 14.76 Granted 713 13.75 Vested (152 ) 15.39 Cancelled or forfeited (98 ) 14.88 Balance—June 30, 2022 1,286 $ 14.11 The total fair value of RSUs that vested in the six months ended June 30 The fair value of RSUs is determined on the date of grant based on the market price of our common stock on that date. Valuation Assumptions The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Assumptions: Expected term (in years) 6.2 6.1 6.2 6.1 Volatility 77.0 % 78.6 % 77.6 % 79.0 % Risk-free interest rate 2.9 % 1.1 % 2.0 % 0.8 % Dividend yield — — — — Six Months Ended June 30, 2022 2021 Fair Value: Weighted-average grant date fair value per share $ 9.28 $ 10.65 The weighted-average assumptions used to estimate the fair value of our common stock to be issued under the 2015 ESPP using a Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Assumptions: Expected term (in years) 0.5 0.5 0.5 0.5 Volatility 57.1 % 60.9 % 57.1 % 60.9 % Risk-free interest rate 0.0 % 0 % 1.5 % 0 % Dividend yield — — — — Six Months Ended June 30, 2022 2021 Fair Value: Weighted-average grant date fair value per share $ 4.29 $ 5.36 Stock-Based Compensation Expense Total stock Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 2,355 $ 1,732 $ 4,540 $ 2,760 General and administrative 2,405 1,863 4,489 3,313 Total stock-based compensation expense $ 4,760 $ 3,595 $ 9,029 $ 6,073 Total unrecognized stock-based compensation expense and the expected period over which such expense will be recognized are as follows ($ in millions): As of June 30, 2022 Stock options Unrecognized stock compensation expense $ 34.3 Weighted-average remaining vesting period (years) 2.8 RSU Unrecognized stock compensation expense $ 15.1 Weighted-average remaining vesting period (years) 2.2 ESPP Unrecognized stock compensation expense $ 0.2 Weighted-average remaining vesting period (years) 0.4

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes No income tax benefit or expense was recorded for the three and six months ended June 30, 2022. We recorded income tax benefit of $0.7 million for the three and six months ended June 30, 2021. Our effective tax rate was 1.7% and 0.9% for the three and six months ended June 30, 2021. Our effective tax rate is lower than the statutory tax rate of 21% primarily due to us maintaining a full valuation allowance against our net deferred tax assets, offset by deferred tax benefits associated with the sale of certain non-renal assets.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Common Share	16. Net Loss per Common Share The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders, which excludes unvested restricted shares and shares which are legally outstanding, but subject to repurchase by us (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (37,648 ) $ (42,571 ) $ (69,332 ) $ (79,786 ) Denominator: Weighted-average shares outstanding 62,040 44,021 60,244 43,176 Less: weighted-average unvested restricted shares and shares subject to repurchase (57 ) (160 ) (69 ) (172 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 61,983 43,861 60,175 43,004 Net loss per share attributable to common stockholders, basic and diluted $ (0.61 ) $ (0.97 ) (1.15 ) (1.86 ) As of June 30, 2022, 3.6 million and 1.1 million pre-funded warrants to purchase common stock, issued in connection with the November 2021 public offering and the May 2022 public offering, respectively, were included in the weighted-average shares outstanding used in the calculation of basic and diluted net loss per share. Refer to Note 13 “Common Stock” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 17, 2022 and Note 13 “Common Stock” for more information. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Unvested RSUs 1,286 876 1,286 876 Unvested RSAs 46 148 46 148 Options to purchase common stock 6,987 6,414 6,987 6,414 Total 8,319 7,438 8,319 7,438

Basis of Presentation and Con_2

Basis of Presentation and Consolidation, Use of Estimates and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of financial information. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or for any other future year. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2021 included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 17, 2022. The condensed consolidated financial statements include the accounts of Chinook Therapeutics, Inc. and our wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of expenses during the reporting periods. Such estimates include the valuation of intangible assets, acquired property and equipment, investments, contingent value rights (“CVR”) liability, contingent consideration liability, lease right-of-use assets, and lease obligations, as well as
Risks and Uncertainties	Risks and Uncertainties We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of our products and processes and clinical efficacy and safety of our products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. Our product candidates are still in development and, to date, none of our product candidates have been approved for sale and, therefore, we have not generated any revenue from product sales. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate revenue from product sales. We operate in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees, consultants and other third parties.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent Accounting Pronouncements, Not Yet Adopted In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40)

Cash, Cash Equivalents and Ma_2

Cash, Cash Equivalents and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2022
Cash And Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Marketable Securities	Cash, cash equivalents and marketable securities consisted of the following (in thousands): June 30, 2022 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Cash $ 25,004 $ — $ — $ 25,004 Money market funds 53,850 — — 53,850 Commercial paper 62,094 — (10 ) 62,084 U.S. government and agency securities 4,990 — (1 ) 4,989 Total cash and cash equivalents $ 145,938 $ — $ (11 ) $ 145,927 Marketable securities: Commercial paper $ 49,972 $ 1 $ (51 ) $ 49,922 U.S. government and agency securities 143,944 2 (1,275 ) 142,671 Corporate debt securities 67,560 1 (880 ) 66,681 Total marketable securities $ 261,476 $ 4 $ (2,206 ) $ 259,274 December 31, 2021 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and cash equivalents: Cash $ 44,499 $ — $ — $ 44,499 Money market funds 117,023 — — 117,023 Commercial paper 16,898 — (1 ) 16,897 Corporate debt securities 3,306 — (1 ) 3,305 Total cash and cash equivalents $ 181,726 $ — $ (2 ) $ 181,724 Marketable securities: Commercial paper $ 34,978 $ — $ (10 ) $ 34,968 U.S. government and agency securities 85,309 1 (88 ) 85,222 Corporate debt securities 53,172 4 (38 ) 53,138 Total marketable securities $ 173,459 $ 5 $ (136 ) $ 173,328
Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Marketable Securities by Contractual Maturity	The amortized cost and estimated fair value of our available-for-sale marketable securities by contractual maturity are summarized below as of June 30 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Mature in one year or less $ 217,966 $ 2 $ (1,281 ) $ 216,687 Mature after one year through two years 43,510 2 (925 ) 42,587 Total available-for-sale marketable securities $ 261,476 $ 4 $ (2,206 ) $ 259,274

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): June 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 78,854 $ — $ — $ 78,854 Commercial paper — 62,084 — 62,084 U.S. government and agency securities — 4,989 — 4,989 Total cash and cash equivalents 78,854 67,073 — 145,927 Marketable securities: Commercial paper — 49,922 — 49,922 U.S. government and agency securities — 142,671 — 142,671 Corporate debt securities — 66,681 — 66,681 Total marketable securities — 259,274 — 259,274 Total fair value of assets $ 78,854 $ 326,347 $ — $ 405,201 Liabilities: Contingent value rights liability $ — $ — $ 25,009 $ 25,009 Contingent consideration liability — — 4,220 4,220 Total fair value of liabilities $ — $ — $ 29,229 $ 29,229 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Cash and money market funds $ 161,522 $ — $ — $ 161,522 Commercial paper — 16,897 — 16,897 Corporate debt securities — 3,305 — 3,305 Total cash and cash equivalents 161,522 20,202 — 181,724 Marketable securities: Commercial paper — 34,968 — 34,968 U.S. government and agency securities — 85,222 — 85,222 Corporate debt securities — 53,138 — 53,138 Total marketable securities — 173,328 — 173,328 Total fair value of assets $ 161,522 $ 193,530 $ — $ 355,052 Liabilities: Contingent value rights liability $ — $ — $ 34,591 $ 34,591 Contingent consideration liability — — 5,160 5,160 Total fair value of liabilities $ — $ — $ 39,751 $ 39,751
Summary of Changes in Fair Value of Level 3 Financial Instruments	The following table presents a summary of the changes in the fair value of our Level 3 financial instruments (in thousands): Contingent Value Rights Liability Contingent Consideration Liability Balance at December 31, 2021 $ 34,591 $ 5,160 Net change in fair value upon remeasurement (2,082 ) (940 ) Payment of contingent value rights liability (7,500 ) — Balance at June 30, 2022 $ 25,009 $ 4,220

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2022 2021 Research and lab equipment $ 3,405 $ 3,366 Computer equipment and software 1,349 1,497 Furniture and fixtures 1,346 1,224 Leasehold improvements 17,010 16,976 Total property and equipment 23,110 23,063 Total accumulated depreciation (5,610 ) (4,128 ) Property and equipment, net $ 17,500 $ 18,935

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The gross carrying amounts and net book value of intangible assets were as follows (in thousands): June 30, 2022 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 2,752 $ 23,933 In-place lease 1,433 215 1,218 Total intangible assets with finite lives 28,118 2,967 25,151 Acquired in-process research & development ("IPR&D") assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 2,967 $ 61,701 December 31, 2021 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: Acquired license agreement $ 26,685 $ 1,968 $ 24,717 In-place lease 1,433 141 1,292 Total intangible assets with finite lives 28,118 2,109 26,009 Acquired IPR&D assets 36,550 — 36,550 Total intangible and acquired IPR&D assets $ 64,668 $ 2,109 $ 62,559
Schedule of Finite-Lived Intangible Assets Estimated Future Amortization Expense	Based on finite-lived intangible assets recorded as of June 30 Year Ending December 31, Estimated Amortization Expense 2022 (remaining six months) $ 864 2023 1,733 2024 1,733 2025 1,733 2026 1,733 Thereafter 17,355

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities And Other Liabilities [Abstract]
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities consisted of the following (in thousands): June 30, December 31, 2022 2021 Research and development costs $ 11,157 $ 8,397 Compensation and benefits 4,844 6,455 Sublease rent and security deposit 299 1,067 Business taxes and licensing fees 331 421 Consulting and outside services 711 424 Other 31 340 Total accrued and other current liabilities $ 17,373 $ 17,104

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Schedule of Maturity of Operating Lease Liabilities	The maturity of our operating lease liabilities as of June 30, 2022 is as follows (in thousands): Undiscounted Lease Payments Amounts 2022 (remaining six months) $ 3,800 2023 7,695 2024 7,850 2025 8,009 2026 7,158 Thereafter 18,919 Total undiscounted lease payments 53,431 Present value adjustment (11,564 ) Total net lease liability $ 41,867 Net lease liability – current $ 4,701 Net lease liability - non-current 37,166 Total net lease liability $ 41,867
Schedule of Additional Information Related to Operating Leases	The following summarizes additional information related to our operating leases: June 30, 2022 December 31, 2021 Weighted-average remaining lease terms (in years) Operating leases 6.9 7.4 Weighted-average discount rate Operating leases 7.5% 7.5%

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2022
Restricted Stock Awards (RSAs)
Summary of RSA Activity	The following table summarizes RSA activity: RSAs Outstanding Number of RSAs (in thousands) Weighted- Average Grant Date Fair Value Per Share Balance—December 31, 2021 99 $ 0.00034 Vested (47 ) 0.00034 Cancelled or forfeited (6 ) 0.00034 Balance—June 30, 2022 46 $ 0.00034

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Stock Option Activity	Stock option activity under the Plans is set forth below: Number of Shares Underlying Options (in thousands) Weighted- Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Balance—December 31, 2021 5,842 $ 12.73 $ 7.00 $ 34,928 Granted 2,026 13.49 Exercised (356 ) 7.26 Canceled or forfeited (525 ) 12.99 Balance—June 30, 2022 6,987 $ 13.21 $ 7.52 $ 42,093 Options exercisable—June 30, 2022 2,802 $ 14.47 $ 5.41 $ 20,580 Options vested and expected to vest—June 30, 2022 6,987 $ 13.21 $ 7.52 $ 42,093
Summary of Restricted Stock Units ("RSU") Activity (Details)	Restricted stock unit (“RSU”) activity under the Plans is set forth below: RSUs Outstanding Number of RSUs (in thousands) Weighted- Average Grant Date Fair Share Balance—December 31, 2021 823 $ 14.76 Granted 713 13.75 Vested (152 ) 15.39 Cancelled or forfeited (98 ) 14.88 Balance—June 30, 2022 1,286 $ 14.11
Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Stock Options Using Black Scholes Option-Pricing Model	The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Assumptions: Expected term (in years) 6.2 6.1 6.2 6.1 Volatility 77.0 % 78.6 % 77.6 % 79.0 % Risk-free interest rate 2.9 % 1.1 % 2.0 % 0.8 % Dividend yield — — — — Six Months Ended June 30, 2022 2021 Fair Value: Weighted-average grant date fair value per share $ 9.28 $ 10.65
Summary of Stock-Based Compensation	Total stock Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 2,355 $ 1,732 $ 4,540 $ 2,760 General and administrative 2,405 1,863 4,489 3,313 Total stock-based compensation expense $ 4,760 $ 3,595 $ 9,029 $ 6,073
Total Unrecognized Stock-Based Compensation Expense and Expected Period Over Which Such Expense Will Be Recognized	Total unrecognized stock-based compensation expense and the expected period over which such expense will be recognized are as follows ($ in millions): As of June 30, 2022 Stock options Unrecognized stock compensation expense $ 34.3 Weighted-average remaining vesting period (years) 2.8 RSU Unrecognized stock compensation expense $ 15.1 Weighted-average remaining vesting period (years) 2.2 ESPP Unrecognized stock compensation expense $ 0.2 Weighted-average remaining vesting period (years) 0.4
2015 ESPP
Schedule of Black Scholes Option-Pricing Model	The weighted-average assumptions used to estimate the fair value of our common stock to be issued under the 2015 ESPP using a Black-Scholes option-pricing model and the resulting weighted-average grant date fair value were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Assumptions: Expected term (in years) 0.5 0.5 0.5 0.5 Volatility 57.1 % 60.9 % 57.1 % 60.9 % Risk-free interest rate 0.0 % 0 % 1.5 % 0 % Dividend yield — — — — Six Months Ended June 30, 2022 2021 Fair Value: Weighted-average grant date fair value per share $ 4.29 $ 5.36

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders, which excludes unvested restricted shares and shares which are legally outstanding, but subject to repurchase by us (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (37,648 ) $ (42,571 ) $ (69,332 ) $ (79,786 ) Denominator: Weighted-average shares outstanding 62,040 44,021 60,244 43,176 Less: weighted-average unvested restricted shares and shares subject to repurchase (57 ) (160 ) (69 ) (172 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 61,983 43,861 60,175 43,004 Net loss per share attributable to common stockholders, basic and diluted $ (0.61 ) $ (0.97 ) (1.15 ) (1.86 )
Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	As of June 30, 2022, 3.6 million and 1.1 million pre-funded warrants to purchase common stock, issued in connection with the November 2021 public offering and the May 2022 public offering, respectively, were included in the weighted-average shares outstanding used in the calculation of basic and diluted net loss per share. Refer to Note 13 “Common Stock” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 17, 2022 and Note 13 “Common Stock” for more information. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Unvested RSUs 1,286 876 1,286 876 Unvested RSAs 46 148 46 148 Options to purchase common stock 6,987 6,414 6,987 6,414 Total 8,319 7,438 8,319 7,438

Basis of Presentation and Con_3

Basis of Presentation and Consolidation, Use of Estimates and Recent Accounting Pronouncements - Additional Information (Details)	Jun. 30, 2022
Accounting Policies [Abstract]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, Accounting Standards Update, Adoption Date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect	true

Reverse Merger and Contingent_2

Reverse Merger and Contingent Value Rights - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Description of contingent value rights granted	one CVR for each outstanding share of Aduro common stock

Cash, Cash Equivalents and Ma_3

Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	$ 145,938	$ 181,726
Cash and cash equivalents, Unrealized losses	(11)	(2)
Cash and cash equivalents, Estimated Fair Value	145,927	181,724
Marketable securities, Amortized cost	261,476	173,459
Marketable securities, Unrealized gains	4	5
Marketable securities, Unrealized losses	(2,206)	(136)
Marketable securities, Estimated Fair Value	259,274	173,328
Cash
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	25,004	44,499
Cash and cash equivalents, Estimated Fair Value	25,004	44,499
Money Market Funds
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	53,850	117,023
Cash and cash equivalents, Estimated Fair Value	53,850	117,023
Commercial Paper
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	62,094	16,898
Cash and cash equivalents, Unrealized losses	(10)	(1)
Cash and cash equivalents, Estimated Fair Value	62,084	16,897
Marketable securities, Amortized cost	49,972	34,978
Marketable securities, Unrealized gains	1
Marketable securities, Unrealized losses	(51)	(10)
Marketable securities, Estimated Fair Value	49,922	34,968
U.S. Government and Agency Securities
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost	4,990
Cash and cash equivalents, Unrealized losses	(1)
Cash and cash equivalents, Estimated Fair Value	4,989
Marketable securities, Amortized cost	143,944	85,309
Marketable securities, Unrealized gains	2	1
Marketable securities, Unrealized losses	(1,275)	(88)
Marketable securities, Estimated Fair Value	142,671	85,222
Corporate Debt Securities
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized cost		3,306
Cash and cash equivalents, Unrealized losses		(1)
Cash and cash equivalents, Estimated Fair Value		3,305
Marketable securities, Amortized cost	67,560	53,172
Marketable securities, Unrealized gains	1	4
Marketable securities, Unrealized losses	(880)	(38)
Marketable securities, Estimated Fair Value	$ 66,681	$ 53,138

Cash, Cash Equivalents and Ma_4

Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Mature in one year or less, Amortized cost	$ 217,966
Mature after one year through two years, Amortized cost	43,510
Marketable securities, Amortized cost	261,476	$ 173,459
Mature in one year or less, Unrealized gains	2
Mature after one year through two years, Unrealized gains	2
Total available-for-sale marketable securities, Unrealized gains	4	5
Mature in one year or less, Unrealized losses	(1,281)
Mature after one year through two years, Unrealized losses	(925)
Total available-for-sale marketable securities, Unrealized losses	(2,206)	(136)
Mature in one year or less, Estimated Fair Value	216,687
Mature after one year through two years, Estimated Fair Value	42,587
Total available-for-sale marketable securities, Estimated Fair Value	$ 259,274	$ 173,328

Cash, Cash Equivalents and Ma_5

Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)	Jun. 30, 2022 USD ($)
Cash And Cash Equivalents [Abstract]
Investment in portfolio temporary impaired	$ 0

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Cash and cash equivalents, Estimated Fair Value	$ 145,927	$ 181,724
Marketable securities	259,274	173,328
Assets	405,201	355,052
Liabilities:
Liabilities	29,229	39,751
Contingent Value Rights Liability
Liabilities:
Liabilities	25,009	34,591
Contingent Consideration Liability
Liabilities:
Liabilities	4,220	5,160
Cash and Money Market Funds
Assets:
Cash and cash equivalents, Estimated Fair Value	78,854	161,522
Commercial Paper
Assets:
Cash and cash equivalents, Estimated Fair Value	62,084	16,897
Marketable securities	49,922	34,968
U.S. Government and Agency Securities
Assets:
Cash and cash equivalents, Estimated Fair Value	4,989
Marketable securities	142,671	85,222
Corporate Debt Securities
Assets:
Cash and cash equivalents, Estimated Fair Value		3,305
Marketable securities	66,681	53,138
Level 1
Assets:
Cash and cash equivalents, Estimated Fair Value	78,854	161,522
Assets	78,854	161,522
Level 1 | Cash and Money Market Funds
Assets:
Cash and cash equivalents, Estimated Fair Value	78,854	161,522
Level 2
Assets:
Cash and cash equivalents, Estimated Fair Value	67,073	20,202
Marketable securities	259,274	173,328
Assets	326,347	193,530
Level 2 | Commercial Paper
Assets:
Cash and cash equivalents, Estimated Fair Value	62,084	16,897
Marketable securities	49,922	34,968
Level 2 | U.S. Government and Agency Securities
Assets:
Cash and cash equivalents, Estimated Fair Value	4,989
Marketable securities	142,671	85,222
Level 2 | Corporate Debt Securities
Assets:
Cash and cash equivalents, Estimated Fair Value		3,305
Marketable securities	66,681	53,138
Level 3
Liabilities:
Liabilities	29,229	39,751
Level 3 | Contingent Value Rights Liability
Liabilities:
Liabilities	25,009	34,591
Level 3 | Contingent Consideration Liability
Liabilities:
Liabilities	$ 4,220	$ 5,160

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Contingent Value Rights Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at December 31, 2021	$ 34,591
Net change in fair value upon remeasurement	(2,082)
Payment of contingent value rights liability	(7,500)
Balance at June 30, 2022	25,009
Contingent Consideration Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at December 31, 2021	5,160
Net change in fair value upon remeasurement	(940)
Balance at June 30, 2022	$ 4,220

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - CVR Agreement - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of contingent consideration liability and contingent value rights liability		$ 19.6	$ (10.5)	$ 21.4
Percentage of net proceeds received from transaction of liquidation event			50%
Higher Discount Rates in 2022 and Decrease in Estimated Value of Preferred Shares in Sairopa
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of contingent consideration liability and contingent value rights liability	$ (2)		$ (3)
Development Milestone Recognized In Fourth Quarter of 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Payment related to contingent value rights	$ 7.5

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Total property and equipment	$ 23,110	$ 23,063
Total accumulated depreciation	(5,610)	(4,128)
Property and equipment, net	17,500	18,935
Research and Lab Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	3,405	3,366
Computer Equipment And Software
Property Plant And Equipment [Line Items]
Total property and equipment	1,349	1,497
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	1,346	1,224
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 17,010	$ 16,976

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Depreciation and amortization expense for property and equipment	$ 800	$ 800	$ 1,700	$ 1,500
Property and equipment, net	17,500		17,500		$ 18,935
Canada
Property Plant And Equipment [Line Items]
Property and equipment, net	$ 2,600		$ 2,600

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 117		$ 117		$ 117
Amortization of intangible assets	$ 429	$ 422	$ 858	$ 842
Novartis
Goodwill And Intangible Assets [Line Items]
Intangible assets, weighted average period			16 years 8 months 12 days
Novartis | Minimum
Goodwill And Intangible Assets [Line Items]
Intangible assets, amortization period			9 years
Novartis | Maximum
Goodwill And Intangible Assets [Line Items]
Intangible assets, amortization period			17 years

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	$ 28,118	$ 28,118
Finite Lived Intangible Assets, Accumulated Amortization	2,967	2,109
Intangible assets, net	25,151	26,009
Intangible Assets, Gross Carrying Amount	64,668	64,668
Intangible assets, Net Book Value	61,701	62,559
Acquired IPR&D assets
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets, Gross Carrying Amount	36,550	36,550
Indefinite-Lived Intangible Assets, Net Book Value	36,550	36,550
Acquired license agreement
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	26,685	26,685
Finite Lived Intangible Assets, Accumulated Amortization	2,752	1,968
Intangible assets, net	23,933	24,717
In Place Lease
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	1,433	1,433
Finite Lived Intangible Assets, Accumulated Amortization	215	141
Intangible assets, net	$ 1,218	$ 1,292

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets Estimated Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2022 (remaining six months)	$ 864
2023	1,733
2024	1,733
2025	1,733
2026	1,733
Thereafter	$ 17,355

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accrued Liabilities And Other Liabilities [Abstract]
Research and development costs	$ 11,157	$ 8,397
Compensation and benefits	4,844	6,455
Sublease rent and security deposit	299	1,067
Business taxes and licensing fees	331	421
Consulting and outside services	711	424
Other	31	340
Total accrued and other current liabilities	$ 17,373	$ 17,104

Investment in Equity Securiti_2

Investment in Equity Securities - Additional Information (Details) - San Reno - USD ($) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended	6 Months Ended
	Nov. 30, 2021	Jun. 30, 2022	Jun. 30, 2022
Investment In Equity Securities [Line Items]
Investment in equity security, ownership percentage	50%
Investment in equity securities	$ 40,000,000
Warrants to purchase common shares	5
Exercise price of warrants	$ 0.01
Warrant exercise period	5 years
Fair value of warrant	$ 1,200,000
Equity securities invested amount	$ 40,000,000
Investment in equity security, remaining ownership percentage	50%
Investment in equity securities		$ 41,200,000	$ 41,200,000
Impairment on investment		0	0
Dividends declared on investment in equity securities		$ 0	$ 0
Series A Preferred Stock
Investment In Equity Securities [Line Items]
Investment in equity securities	$ 40,000,000
Dividends percentage	8%

Equity Method Investment - Addi

Equity Method Investment - Additional Information (Details) € in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)	Apr. 30, 2021 EUR (€)
Sairopa B.V.
Schedule Of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	44%
Equity method investment, initial capitalization | €		€ 12.5
Equity method investment, recorded | $	$ 10
Equity method investment, income or loss recorded term	one quarter lag
CVR Agreement
Schedule Of Equity Method Investments [Line Items]
Percentage of net proceeds received from transaction of liquidation event	50%
CVR Agreement | Sairopa B.V.
Schedule Of Equity Method Investments [Line Items]
Percentage of net proceeds received from transaction of liquidation event	50%

Collaboration and License Agr_2

Collaboration and License Agreements - Additional Information (Details) - USD ($) shares in Millions	1 Months Ended		3 Months Ended			6 Months Ended
	Nov. 30, 2021	Dec. 31, 2019	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
China License Agreement | San Reno
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Consideration received as preferred shares	$ 40,000,000
Consideration received as warrants	$ 1,200,000
Revenue recognized			$ 400,000			$ 3,100,000
China License Agreement | San Reno | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Progress-dependent milestone receivable						25,000,000
AbbVie Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares issued		2
Proceeds from issuance of common stock		$ 6,700,000
Milestone payment			0		$ 0	0	$ 0
AbbVie Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent development, regulatory and commercial milestone payments		$ 135,000,000
Merck
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized				$ 10,000
Merck | Maximum | Product Candidate
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates						287,000,000
Merck | Maximum | Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates						135,000,000
Lilly Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized			$ 100,000			400,000
Milestone amount eligible to receive for products or product candidates						$ 464,900,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft² LeaseFacility	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft² LeaseFacility	Jun. 30, 2021 USD ($)
Operating Leased Assets [Line Items]
Number of lease facility | LeaseFacility		4		4
Aggregate sublease income to be earned				$ 61,100,000
Letter of credit outstanding		$ 1,800,000		1,800,000
Operating leases rent expense		2,300,000	$ 2,100,000	4,700,000	$ 4,100,000
Operating leases variable lease payments		800,000		1,600,000	1,200,000
Seattle Sublease
Operating Leased Assets [Line Items]
Sublease agreement term	2021-06
Sublease commencement date	Jul. 01, 2021
Sublease period	58 months
Aggregate estimated base rent payments	$ 4,800,000
Letter of credit outstanding		$ 300,000		$ 300,000
Sublease | CANADA
Operating Leased Assets [Line Items]
Total square footage of leased property | ft²		112,000		112,000
Sublease Income		$ 2,000,000	1.4	$ 4,000,000	$ 2.6
Minimum
Operating Leased Assets [Line Items]
Operating lease, remaining lease term		4 years		4 years
Maximum
Operating Leased Assets [Line Items]
Operating lease, remaining lease term		8 years		8 years
Operating leases variable lease payments			$ 600,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Maturity of Company's Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
2022 (remaining six months)	$ 3,800
2023	7,695
2024	7,850
2025	8,009
2026	7,158
Thereafter	18,919
Total undiscounted lease payments	53,431
Present value adjustment	(11,564)
Total net lease liability	41,867
Net lease liability – current	4,701	$ 4,401
Net lease liability - non-current	37,166	$ 39,589
Total net lease liability	$ 41,867

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Details)	Jun. 30, 2022	Dec. 31, 2021
Weighted-average remaining lease terms (in years)
Operating leases	6 years 10 months 24 days	7 years 4 months 24 days
Weighted-average discount rate
Operating leases	7.50%	7.50%

Common Stock - Additional Infor

Common Stock - Additional Information (Details) $ / shares in Units, $ in Millions	1 Months Ended			6 Months Ended
	May 31, 2022 USD ($) Day $ / shares shares	Nov. 30, 2021 shares	Apr. 30, 2021 USD ($) shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 $ / shares
Class Of Stock [Line Items]
Common stock par value per share | $ / shares				$ 0.0001		$ 0.0001
Restricted Stock Awards (RSAs)
Class Of Stock [Line Items]
Fair value of RSAs vested				$ 0.7	$ 0.8
Underwritten Public Offering
Class Of Stock [Line Items]
Issuance of common stock (in shares) | shares	7,600,000
Shares price per share | $ / shares	$ 14
Underwritten Public Offering | Accounting Standards Update 2017-11
Class Of Stock [Line Items]
Shares price per share | $ / shares	$ 14
Underwriters
Class Of Stock [Line Items]
Issuance of common stock (in shares) | shares	1,100,000
Pre-Funded Warrants
Class Of Stock [Line Items]
Issuance of common stock (in shares) | shares	1,100,000	3,600,000
Shares price per share | $ / shares	$ 13.9999
Common stock par value per share | $ / shares	$ 0.0001
Minimum number of days to prior notice | Day	61
Pre-Funded Warrants | Accounting Standards Update 2017-11
Class Of Stock [Line Items]
Issuance of common stock (in shares) | shares	1,100,000			3,600,000
Shares price per share | $ / shares	$ 13.9999
Common stock par value per share | $ / shares	$ 0.0001
Shares sale price	$ 15
Number of warrants exercised | shares	0			0
Pre-Funded Warrants | Minimum
Class Of Stock [Line Items]
Ownership percentage of number of shares of common stock outstanding immediately after effect to exercise	4.99%
Pre-Funded Warrants | Maximum
Class Of Stock [Line Items]
Increase (decrease) percentage in number of shares of common stock outstanding immediately after effect of exercise	19.99%
Underwritten Public Offering
Class Of Stock [Line Items]
Proceeds from issuance of common stock	$ 120.7
Underwriting discounts and commissions and estimated offering expenses	7.7
Proceeds from issuance of common stock	$ 120.7
At-the-Market Offering | 2021 Sales Agreement | Cantor Fitzgerald & Co. and SVB Leerink LLC
Class Of Stock [Line Items]
Issuance of common stock (in shares) | shares			2,200,000
Proceeds from issuance of common stock			$ 33.9
Commission on sales of common stock, percentage			3%
Proceeds from issuance of common stock			$ 33.9
Aggregate offering available for issuance of common stock			$ 40
Agreement maturity date			Apr. 07, 2024
At-the-Market Offering | Maximum | 2021 Sales Agreement | Cantor Fitzgerald & Co. and SVB Leerink LLC
Class Of Stock [Line Items]
Aggregate offering price from offer and sale of common stock			$ 75

Common Stock - Summary of RSA A

Common Stock - Summary of RSA Activity (Details) - Restricted Stock Awards (RSAs)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Restricted Stock, Beginning balance | shares	99,000
Number of Restricted Stock, Vested | shares	(47,000)
Number of Restricted Stock, Cancelled or forfeited | shares	(6,000)
Number of Restricted Stock, Ending balance | shares	46,000
Weighted-Average Grant Date Fair Value per Share, Beginning Balance | $ / shares	$ 0.00034
Weighted-Average Grant Date Fair Value per Share, Vested | $ / shares	0.00034
Weighted-Average Grant Date Fair Value per Share, Cancelled or forfeited | $ / shares	0.00034
Weighted-Average Grant Date Fair Value per Share, Ending Balance | $ / shares	$ 0.00034

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) IncentivePlan shares	Jun. 30, 2021 USD ($) shares	Dec. 31, 2021 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans | IncentivePlan	2
Number of common shares, granted	2,026,000
Common Stock options exercised	356,000	200,000
Intrinsic value of options exercised | $	$ 2.7	$ 2.5
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of restricted stock units vested during the period | $	$ 2.2	$ 0.2
2009 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares, granted	0
Number of shares available for future grant	1,700,000		1,400,000
2015 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future grant	1,200,000		700,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Underlying Options, Beginning balance	5,842
Number of Shares Underlying Options, Granted	2,026
Number of Shares Underlying Options, Exercised	(356)	(200)
Number of Shares Underlying Options, Cancelled or forfeited	(525)
Number of Shares Underlying Options, Ending balance	6,987		5,842
Number of Shares Underlying Options, Options exercisable	2,802
Number of Shares Underlying Options, Vested and expected to vest	6,987
Options Outstanding, Weighted-Average Exercise Price, Beginning balance	$ 12.73
Options Outstanding, Weighted-Average Exercise Price, Granted	13.49
Options Outstanding, Weighted-Average Exercise Price, Exercised	7.26
Options Outstanding, Weighted-Average Exercise Price, Canceled or forfeited	12.99
Options Outstanding, Weighted-Average Exercise Price, Ending balance	13.21		$ 12.73
Options Outstanding, Weighted-Average Exercise Price, Options exercisable	14.47
Options Outstanding, Weighted-Average Exercise Price, Options vested and expected to vest	$ 13.21
Options Outstanding, Weighted Average Remaining Contractual Term, Beginning balance	7 years 6 months 7 days		7 years
Options exercisable, Weighted Average Remaining Contractual Term	5 years 4 months 28 days
Options vested and expected to vest, Weighted Average Remaining Contractual Term	7 years 6 months 7 days
Options Outstanding, Aggregate Intrinsic Value, Balance	$ 42,093		$ 34,928
Options Outstanding, Aggregate Intrinsic Value, Options exercisable-June 30, 2022	20,580
Options Outstanding, Aggregate Intrinsic Value, Options vested and expected to vest-June 30, 2022	$ 42,093

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Units ("RSU") Activity (Details) - Restricted Stock Units (RSUs) shares in Thousands	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Restricted Stock, Beginning balance | shares	823
Number of Restricted Stock, Granted | shares	713
Number of Restricted Stock, Vested | shares	(152)
Number of Restricted Stock, Cancelled or forfeited | shares	(98)
Number of Restricted Stock, Ending balance | shares	1,286
Weighted-Average Grant Date Fair Value per Share, Beginning Balance | $ / shares	$ 14.76
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares	13.75
Weighted-Average Grant Date Fair Value per Share, Vested | $ / shares	15.39
Weighted-Average Grant Date Fair Value per Share, Cancelled or forfeited | $ / shares	14.88
Weighted-Average Grant Date Fair Value per Share, Ending Balance | $ / shares	$ 14.11

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Stock Options Using Black Scholes Option-Pricing Model (Details) - Stock Options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 2 months 12 days	6 years 1 month 6 days	6 years 2 months 12 days	6 years 1 month 6 days
Volatility	77%	78.60%	77.60%	79%
Risk-free interest rate	2.90%	1.10%	2%	0.80%
Weighted-average grant date fair value per share			$ 9.28	$ 10.65

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Black Scholes Option-Pricing Model (Details) - 2015 ESPP - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months	6 months	6 months	6 months
Volatility	57.10%	60.90%	57.10%	60.90%
Risk-free interest rate	0%	0%	1.50%	0%
Weighted-average grant date fair value per share			$ 4.29	$ 5.36

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,760	$ 3,595	$ 9,029	$ 6,073
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	2,355	1,732	4,540	2,760
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,405	$ 1,863	$ 4,489	$ 3,313

Stock-Based Compensation - Tota

Stock-Based Compensation - Total Unrecognized Stock-Based Compensation Expense and Expected Period Over Which Such Expense Will Be Recognized (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock compensation expense	$ 34.3
Weighted-average remaining vesting period (years)	2 years 9 months 18 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average remaining vesting period (years)	2 years 2 months 12 days
Unrecognized stock compensation expense	$ 15.1
2015 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average remaining vesting period (years)	4 months 24 days
Unrecognized stock compensation expense	$ 0.2

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income tax benefit	$ 0	$ 741,000	$ 0	$ 741,000
Effective income tax rate		1.70%		0.90%
Statutory tax rate			21%

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net loss	$ (37,648)	$ (31,684)	$ (42,571)	$ (37,215)	$ (69,332)	$ (79,786)
Weighted-average shares outstanding	62,040		44,021		60,244	43,176
Less: weighted-average unvested restricted shares and shares subject to repurchase	(57)		(160)		(69)	(172)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	61,983		43,861		60,175	43,004
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	61,983		43,861		60,175	43,004
Net loss per share attributable to common stockholders, basic	$ (0.61)		$ (0.97)		$ (1.15)	$ (1.86)
Net loss per share attributable to common stockholders, diluted	$ (0.60)		$ (0.97)		$ (1.15)	$ (1.86)

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Details) - shares shares in Millions	1 Months Ended
	May 31, 2022	Nov. 30, 2021
Pre-Funded Warrants
Earnings Per Share Basic [Line Items]
Issuance of common stock (in shares)	1.1	3.6

Net Loss per Common Share - S_2

Net Loss per Common Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	8,319,000	7,438,000	8,319,000	7,438,000
Unvested RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	1,286,000	876,000	1,286,000	876,000
Unvested RSAs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	46,000	148,000	46,000	148,000
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share would have been antidilutive	6,987,000	6,414,000	6,987,000	6,414,000